Insulin receptor tyrosine kinase substrate

• US 5,891,674 A
• Filed: 06/19/1997
• Issued: 04/06/1999
• Est. Priority Date: 06/19/1997
• Status: Expired due to Fees

• Current Assignee: DuPont Performance Elastomers L (Bristol-Myers Squibb Company)
• Original Assignee: Incyte Pharmaceuticals, Inc.
• Inventors: Hillman, Jennifer L., Lal, Preeti, Shah, Purvi
• Primary Examiner(s): Feisee, Lila
• Assistant Examiner(s): LAZAR WESLEY, ELIANE M
• Application Number:
  US08/878,563
• Time in Patent Office: 656 Days
• Field of Search: 435/69.1, 435/320.1, 435/325, 435/252.3, 536/23.5, 536/23.1, 530/350
• US Class Current: 435/69.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 14/47 from mammals

Abstract

The invention provides a human insulin receptor tyrosine kinase substrate (IRS-p53h) and polynucleotides which identify and encode IRS-p53h. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of IRS-p53h.

Claims

1. A substantially purified polypeptide comprising the amino acid sequence of SEQ ID NO:

1.

2. An isolated and purified polynucleotide sequence encoding the polypeptide of claim 1.

3. A composition comprising the polynucleotide sequence of claim 2 and an acceptable carrier.

4. A polynucleotide sequence which hybridizes under conditions including washing under stringent wash conditions of 0.1×

saline sodium citrate and 0.5% sodium dodecyl sulfate at room temperature to the polynucleotide sequence of claim 2.

5. An isolated and purified polynucleotide sequence which is fully complementary to the polynucleotide sequence of claim 2.

9. An expression vector comprising the polynucleotide sequence of claim 2.

10. A host cell containing the expression vector of claim 9.

11. A method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:

1, the method comprising the steps of;

a) culturing the host cell of claim 10 under conditions suitable for the expression of the polypeptide; and

b) recovering the polypeptide from the host cell culture.

6. An isolated and purified polynucleotide sequence comprising SEQ ID NO:

2.

7. A composition comprising the polynucleotide sequence of claim 6 and an acceptable carrier.

8. An isolated and purified polynucleotide sequence which is fully complementary to the polynucleotide sequence of claim 6.

12. A composition comprising a substantially purified polypeptide having the amino acid sequence of SEQ ID NO:

1 in conjunction with a pharmaceutically acceptable carrier.